Sunstone Life Science Ventures

Sunstone Life Science Ventures

Sten Verland launched Sunstone Life Science Ventures in 2007 as an independent European firm focused solely on early-stage therapeutics. Headquartered in Copenhagen, Sunstone was purpose-built to bridge academic research and clinical development, and it has since contributed to bringing several new drugs to market. The firm is supported by financial backing from the European Union via the InnovFin Equity facility and the European Fund for Strategic Investments. Sunstone targets companies developing novel human therapeutics, deploying capital across pre-clinical through Phase 3 clinical programs. The strategy is executed through a series of sector-dedicated venture funds rather than a single commingled pool. The firm publishes a portfolio of active investments, completed M&A exits, and companies that have reached public markets. Geographic emphasis concentrates on European innovation hubs, with a footprint spanning Denmark and the broader continent. The firm operates out of Frederiksberg, Denmark, and executes its strategy through a team drawn from scientific and operational backgrounds. Principals include Sten Verland, who serves as Managing Partner. Sunstone maintains a transparent portfolio section on its website, categorizing positions as active investments, completed IPOs, and completed M&A exits. Sunstone’s architecture as a dedicated, life-science-only venture platform — investing solely in human therapeutics and managing multiple discrete fund vintages — distinguishes it from generalist European VC firms. Its integration with EU strategic investment instruments provides a backstop that couples public-policy objectives with venture returns, a structure that aligns capital with long clinical development timelines.